HOME >> BIOLOGY >> NEWS
Link identified between Alzheimer's disease and glaucoma

UK scientists have shown for the first time that key proteins involved in Alzheimer's disease are also implicated in glaucoma, the major cause of irreversible blindness worldwide. Research carried out at the UCL Institute of Ophthalmology and funded by the Wellcome Trust has also shown that novel drugs being trialled for Alzheimer's disease which target this protein may be used to treat glaucoma.

The research team has developed a new technology for visualising nerve cell damage in the retina, known as Detection of Apoptosing Retinal Cells. Using this technology, they demonstrated that the protein beta-amyloid, which causes the so-called "plaque" lesions in the brains of Alzheimer's patients, also leads to nerve cell death in the retina. The research is published online today in the journal Proceedings of the National Academy of Sciences of the USA.

"We've seen for the first time that there is a clear link between what causes Alzheimer's disease and one of the basic mechanisms behind glaucoma," says Dr Francesca Cordeiro from University College London, who led the study. Dr Cordeiro is also a consultant ophthalmologist at the Western Eye Hospital, London, specialising in glaucoma. "However, this doesn't mean that everyone with Alzheimer's will develop glaucoma or vice versa. Glaucoma has a number of risk factors."

Glaucoma affects over half a million in the UK and as many as 65 million people worldwide(1). Little is know about what exactly causes the disease, which causes damage to the optic nerve in the eye; although the disease is traditionally attributed to increased pressure in the eye (known as "intraocular pressure", and clinical treatments attempt to lower this pressure). However a significant number of patients continue to lose vision despite their pressure being well controlled. The new research opens up a new avenue of treatment in glaucoma which does not involve treating intraocular pressure.

Dr Cordeiro and colle
'"/>

Contact: Mike Findlay
m.findlay@wellcome.ac.uk
44-207-611-8612
Wellcome Trust
6-Aug-2007


Page: 1 2

Related biology news :

1. Gene identified for Crohns disease in children
2. New gene mutation identified in common type of dementia
3. Allergy molecule identified
4. Gene responsible for common hearing loss identified for first time
5. Muscle weakness: New mutation identified
6. Tumor vessels identified by unique molecular markers
7. Extra-aggressive form of idiopathic pulmonary fibrosis identified
8. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
9. Pediatric cancer stem cell identified: understanding the origin of ERMS
10. New host species for avian influenza identified
11. Master regulatory gene of epithelial stem cells identified

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2019)... ... ... Evan Holden , a shareholder in the Atlanta office ... National Academy of Sciences (NAS) Roundtable on Biomedical Engineering Materials Applications (BEMA), March 25 ... Pharmaceutical, Medical Device & Health Care Litigation Practice , addressed, “Medical Device Liability—How ...
(Date:3/25/2019)... ... March 25, 2019 , ... Ambry Genetics ... genetic testing, today announced a new laboratory services agreement with Clovis Oncology Inc., ... Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... for Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit chemistry ... The five-tube kit is comprised of preformatted master mixes for a simple, fast, ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... SANTA BARBARA, Calif. (PRWEB) , ... April 09, ... ... global professional services firm focused on increasing the capacity of life sciences organizations ... to its Cloud Assurance platform in the past 12 months. , ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & ... leadership team, including a new addition to the presidential line of succession, at the ... join the Society's leadership team for a three-year term (2019-2021). , All five incoming ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... solutions, announced it would be releasing it’s latest field-ready solution for performing PCR, ... Biomeme’s next-gen thermocycler Franklin™ pays homage to Rosland Franklin, an English chemist and ...
Breaking Biology Technology:
Cached News: